Synflorix® vaccine   

This product is manufactured by GlaxoSmithKline using the ingredient pneumococcal conjugate vaccine adsorbed (Pneu-C-10).

This product is taken via intramuscular injection.

Why is it prescribed?

Pneumococcal conjugate vaccine adsorbed is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against invasive diseases (e.g. meningitis), pneumonia and blood infection caused by the 10 strains of pneumococci contained in the vaccine.

  • Synflorix® is a vaccine that will help protect your child against diseases caused by some types of a bacteria called Streptoccus pneumoniae. This bacteria can cause serious illnesses including meningitis and blood infections.
  • Synflorix® works by helping the body to make its own antibodies, which protect your child against these diseases.
  • As with all vaccines, Synflorix® may not fully protect all children who are vaccinated.
  • This vaccine should only be administered by qualified health care practitioners.


See other products used in the treatment of •pneumonia •upper respiratory tract infections •middle ear infections •

The dosing of Synflorix® is age-dependent. The following is a general guide.  Please contact your local public health department for dosing.
For infants 6 weeks to 6 months of age, the primary vaccination schedule consists of three doses of 0.5 mL with an interval of at least 1 month between doses. A booster dose is recommended at least 6 months after the last primary dose and preferably between 12 and 15 months of age.
For infants aged 7-11 months, the vaccination schedule consists of two doses of 0.5 mL with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months between doses.
For children aged 12-23 months, the vaccination schedule consists of two doses of 0.5 mL with an interval of at least 2 months between doses.

Pneumococcal conjugate vaccine adsorbed (Pneu-C-10) is made up of 10 strains of pneumococcal (pneumonia) bacteria combined with carrier proteins. When injected, the vaccine in the body familiarizes the immune system to the pneumococcal bacteria. If the person is exposed to the bacteria again, the immune system can mount a quick, specific attack against the bacteria and ultimately resist infection. Pneumococcal conjugate vaccine adsorbed will not protect against pneumococcal serogroups that are not included in the vaccine.

Like all medicines, this vaccine can cause side effects, although not everybody gets them. The side effects are listed here from those that are very common to those that are rare.
Very common:

  • Pain, redness and swelling at the injection site
  • Fever (38C or higher)
  • Drowsiness
  • Irritability
  • Loss of appetite


  • Hardness at the injection site


  • Blood clot, bleeding and small lump at the injection site
  • Diarrhea, vomiting
  • Unusual crying
  • Temporarily stopping breathing if your child was born prematurely (before or at 28 weeks of pregnancy)


  • Rash, hives, allergic reactions such as skin rash or allergies
  • Fits without temperature or due to high temperature (fever)


As with other vaccines, the administration of Pneumococcal conjugate vaccine adsorbed should be postponed in subjects suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Children with impaired immune responsiveness, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to the vaccination.
The potential risk of apnea and the need for respiratory monitoring for 48-72 hours should be considered when giving the vaccination to very premature infants (born less than or equal to 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
As with other vaccines administered intramuscularly, pneumococcal conjugate vaccine adsorbed should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an IM injection in these subjects.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Use is not recommended in the following situations:

  • prior severe allergic reaction to pneumococcal vaccine
  • allergy to any component of the vaccine

Use in pregnancy and breastfeeding: Pneu-C-13 and Pneu-P-23 vaccines are preferred.



Page Last Updated: 05/10/2016